<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Overview of vitamin K</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Overview of vitamin K</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Overview of vitamin K</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sassan Pazirandeh, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">David L Burns, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">David Seres, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sara Swenson, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Mar 16, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Vitamins are a number of chemically unrelated families of organic substances that cannot be synthesized by humans but need to be ingested in the diet in small quantities to prevent disorders of metabolism. They are divided into water-soluble and fat-soluble vitamins (<a class="graphic graphic_table graphicRef63827" href="/z/d/graphic/63827.html" rel="external">table 1</a>). Vitamin K has a major role in coagulation pathways because it is a cofactor required for the activity of several key proteins containing carboxyglutamic acid residues. <a class="drug drug_general" data-topicid="9771" href="/z/d/drug information/9771.html" rel="external">Vitamin K</a> deficiency is rare except in neonates and patients with predisposing conditions including hepatobiliary or pancreatic disease.</p><p><a class="drug drug_general" data-topicid="9771" href="/z/d/drug information/9771.html" rel="external">Vitamin K</a> antagonists (VKA) are a class of drugs used for therapeutic anticoagulation. The pharmacology and use of these drugs is discussed in separate topic reviews. (See  <a class="medical medical_review" href="/z/d/html/1334.html" rel="external">"Warfarin and other VKAs: Dosing and adverse effects"</a> and  <a class="medical medical_review" href="/z/d/html/1324.html" rel="external">"Management of warfarin-associated bleeding or supratherapeutic INR"</a> and  <a class="medical medical_review" href="/z/d/html/1325.html" rel="external">"Reversal of anticoagulation in intracranial hemorrhage"</a>.)</p><p>This topic review will focus on vitamin K. Overviews of the other fat-soluble vitamins, minerals, and water-soluble vitamins are available elsewhere. (See  <a class="medical medical_review" href="/z/d/html/2571.html" rel="external">"Overview of vitamin A"</a> and  <a class="medical medical_review" href="/z/d/html/2033.html" rel="external">"Overview of vitamin D"</a> and  <a class="medical medical_review" href="/z/d/html/2582.html" rel="external">"Overview of vitamin E"</a> and  <a class="medical medical_review" href="/z/d/html/2585.html" rel="external">"Overview of dietary trace elements"</a> and  <a class="medical medical_review" href="/z/d/html/5367.html" rel="external">"Overview of water-soluble vitamins"</a> and  <a class="medical medical_review" href="/z/d/html/5368.html" rel="external">"Vitamin intake and disease prevention"</a>.)</p><p class="headingAnchor" id="H3"><span class="h1">CHEMISTRY</span><span class="headingEndMark"> — </span>Vitamin K and its derivatives contain a 2-methyl-1,4- naphthoquinone nucleus with a lipophilic side chain (<a class="graphic graphic_figure graphicRef66755" href="/z/d/graphic/66755.html" rel="external">figure 1</a>). The structure is similar to <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">warfarin</a> and other coumarin-like anticoagulants, which function as <a class="drug drug_general" data-topicid="9771" href="/z/d/drug information/9771.html" rel="external">vitamin K</a> antagonists. Vitamin K1 (phylloquinone) has a phytyl side chain. Vitamin K2 (menaquinone) has several forms, each with an isoprenoid side chain, designated MK-4 (or menatetrenone) through MK-13 according to the length of the side chain. The most common form of menaquinone has four residues (MK-4).</p><p class="headingAnchor" id="H4"><span class="h1">METABOLISM</span><span class="headingEndMark"> — </span>Vitamin K absorption requires intact pancreatic and biliary function and fat absorptive mechanisms. Dietary vitamin K is protein-bound and is liberated by the proteolytic action of pancreatic enzymes in the small intestine. Bile salts then solubilize vitamin K into mixed micelles for absorption into enterocytes, where it is incorporated into chylomicrons, thereby facilitating absorption into the intestinal lymphatics and portal circulation for transport to the liver [<a href="#rid1">1</a>]. In the liver it is repackaged into very low-density lipoprotein (VLDL). It circulates in small quantities bound to lipoprotein.</p><p class="headingAnchor" id="H5"><span class="h1">ACTIONS</span><span class="headingEndMark"> — </span>Vitamin K has a major role in coagulation pathways because it is a cofactor required for the activity of several key proteins containing carboxyglutamic acid residues. Several other proteins within the body (eg, osteocalcin) also contain carboxyglutamate residues and depend upon vitamin K for their activity (<a class="graphic graphic_table graphicRef60052" href="/z/d/graphic/60052.html" rel="external">table 2</a>). (See  <a class="medical medical_review" href="/z/d/html/1318.html" rel="external">"Vitamin K-dependent clotting factors: Gamma carboxylation and functions of Gla"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Coagulation</strong> – Vitamin K is essential for activity of several carboxylase enzymes within hepatic cells and is therefore necessary for the activation of coagulation factors VII, IX, X, and prothrombin. These factors contain carboxyglutamic acid, which is carboxylated by gamma-glutamyl carboxylase, an endoplasmic enzyme found in mammalian cells (<a class="graphic graphic_figure graphicRef61632" href="/z/d/graphic/61632.html" rel="external">figure 2</a>) [<a href="#rid2">2,3</a>]. Vitamin K is the active coenzyme in this process, providing energy for the reaction through oxidation [<a href="#rid4">4</a>]. After carboxylation, these proteins gain affinity for the negatively charged phospholipids on the surface of platelets and promote coagulation [<a href="#rid5">5</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Activation of proteins C and S</strong> – The natural anticoagulants proteins S and C also require vitamin K for their antithrombotic activity. Protein C, following its activation by thrombin, inactivates factors Va and VIIIa, thus inhibiting excess generation of thrombin (see  <a class="medical medical_review" href="/z/d/html/1354.html" rel="external">"Protein C deficiency", section on 'Pathophysiology'</a>). Protein S also helps prevent excessive coagulation through its action as a cofactor for activated protein C [<a href="#rid6">6</a>]. (See  <a class="medical medical_review" href="/z/d/html/1357.html" rel="external">"Protein S deficiency"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Reversal of coumarin-like anticoagulants</strong> – Coumarin-like anticoagulants, which are similar in structure to vitamin K (<a class="graphic graphic_figure graphicRef66755" href="/z/d/graphic/66755.html" rel="external">figure 1</a>), interrupt the vitamin K-dependent carboxylation cycle by blocking reduction of the inactive vitamin K 2,3 epoxide to the active form of the vitamin (<a class="graphic graphic_figure graphicRef61632" href="/z/d/graphic/61632.html" rel="external">figure 2</a>) [<a href="#rid7">7</a>]. Vitamin K administration is one of the methods used to reverse the effects of coumarin, including for patients with anticoagulant rodenticide poisoning. (See  <a class="medical medical_review" href="/z/d/html/1324.html" rel="external">"Management of warfarin-associated bleeding or supratherapeutic INR", section on 'Treatment of bleeding'</a> and  <a class="medical medical_review" href="/z/d/html/1325.html" rel="external">"Reversal of anticoagulation in intracranial hemorrhage"</a> and  <a class="medical medical_review" href="/z/d/html/106877.html" rel="external">"Anticoagulant rodenticide poisoning: Management"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Bone formation</strong> – Vitamin K is a cofactor for some proteins involved in bone mineralization, including osteocalcin (bone gamma-carboxyglutamic acid [Gla] protein) and matrix Gla protein (see  <a class="medical medical_review" href="/z/d/html/2053.html" rel="external">"Normal skeletal development and regulation of bone formation and resorption", section on 'Biochemistry of bone mineral matrix'</a>). Clinical trials have examined the use of vitamin K1 (phylloquinone) or vitamin K2 for the treatment of osteoporosis, with conflicting results, which are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/2064.html" rel="external">"Overview of the management of low bone mass and osteoporosis in postmenopausal women"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Coronary vascular calcification</strong> – Matrix Gla protein is dependent on vitamin K-mediated carboxylation for activity. In its active form it is thought to play a role in vascular calcification. Theoretically, <a class="drug drug_general" data-topicid="9771" href="/z/d/drug information/9771.html" rel="external">vitamin K</a> deficiency leads to increased vascular calcification because of lack of matrix Gla protein activity. Vascular calcification predisposes to coronary artery disease. Few trials have assessed the role of vitamin K in coronary artery disease. Those available are not conclusive, but they suggest that further studies are warranted [<a href="#rid8">8,9</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>COVID-19</strong> – In addition to respiratory failure, thromboembolic events are frequent complications of severe COVID-19 infection. <a class="drug drug_general" data-topicid="9771" href="/z/d/drug information/9771.html" rel="external">Vitamin K</a> preferentially actives hepatic procoagulant pathways over extrahepatic anticoagulant protein S. Vitamin K also activates matrix Gla protein, which protects vascular and pulmonary endothelium. Studies demonstrate that uncarboxylated or inactive matrix Gla protein is elevated in COVID-19 patients compared with controls, suggesting that extra-hepatic vitamin K deficiency is associated with poorer outcomes in severe COVID-19 infection [<a href="#rid10">10</a>].</p><p></p><p class="headingAnchor" id="H3960047245"><span class="h1">SOURCES</span><span class="headingEndMark"> — </span>Dietary vitamin K1 (phylloquinone) is found in green vegetables like spinach and broccoli and in some oils (<a class="graphic graphic_table graphicRef78708" href="/z/d/graphic/78708.html" rel="external">table 3</a>) [<a href="#rid7">7</a>]. <a class="drug drug_general" data-topicid="9771" href="/z/d/drug information/9771.html" rel="external">Phytonadione</a> is a synthetic form of vitamin K1.</p><p>Vitamin K2 (menaquinone) is distinguished by an isoprenoid side chain. There are several forms, designated MK-4 through MK-13 according to the length of the side chain. MK-4 (also known as menatetrenone) can be produced from phylloquinone by the body and is the main storage form in animals. The other menaquinones are synthesized by microflora in the gut, providing a portion of the dietary requirement of <a class="drug drug_general" data-topicid="9771" href="/z/d/drug information/9771.html" rel="external">vitamin K</a> [<a href="#rid7">7</a>]. Dietary menaquinones are found in meat (especially liver), cheeses, fermented soybeans, and eggs. However, except for liver and some fermented soy products, the concentrations are low, so most of these foods do not provide a significant portion of dietary vitamin K. The most common forms of vitamin K2 have approximately 60 percent of the activity of vitamin K1, by weight, but the bioavailability of all forms of vitamin K varies substantially depending on other intraluminal nutrients [<a href="#rid1">1,11</a>].</p><p class="headingAnchor" id="H2278130162"><span class="h1">REQUIREMENTS</span></p><p class="headingAnchor" id="H2060522105"><span class="h2">Dietary reference intake</span><span class="headingEndMark"> — </span>The dietary requirement for <a class="drug drug_general" data-topicid="9771" href="/z/d/drug information/9771.html" rel="external">vitamin K</a>, expressed as adequate intake (AI), is 90 micrograms daily in females and 120 micrograms daily in males [<a href="#rid1">1</a>]. The AI in children ranges from 2 micrograms daily in young infants to 75 micrograms daily in adolescent boys (<a class="graphic graphic_table graphicRef81151" href="/z/d/graphic/81151.html" rel="external">table 4</a>). The AI in infants assumes that infants also receive vitamin K prophylaxis at birth (see <a class="local">'Prevention'</a> below and  <a class="medical medical_review" href="/z/d/html/5068.html" rel="external">"Overview of the routine management of the healthy newborn infant", section on 'Vitamin K'</a>). The primary source of vitamin K in most diets is as vitamin K1 (phylloquinone) from leafy green vegetables or oils (<a class="graphic graphic_table graphicRef78708" href="/z/d/graphic/78708.html" rel="external">table 3</a>). A few foods, mainly fermented cheeses, have significant amounts of vitamin K2 (menaquinones).</p><p class="headingAnchor" id="H3509621848"><span class="h2">Special populations</span><span class="headingEndMark"> — </span>Special considerations apply to <a class="drug drug_general" data-topicid="9771" href="/z/d/drug information/9771.html" rel="external">vitamin K</a> requirements in the following populations:</p><p class="headingAnchor" id="H1852915100"><span class="h3">Patients on parenteral nutrition</span><span class="headingEndMark"> — </span>Patients on total <a class="drug drug_general" data-topicid="10307" href="/z/d/drug information/10307.html" rel="external">parenteral nutrition</a> require vitamin K supplementation. Vitamin K is included in most brands of standard multivitamin mix added to the parenteral nutrition solution. A typical daily dose of adult injectable multivitamins for parenteral nutrition includes 150 micrograms of vitamin K1 (<a class="drug drug_general" data-topicid="9771" href="/z/d/drug information/9771.html" rel="external">phytonadione</a>). For patients on <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">warfarin</a>, daily intake of 150 micrograms of vitamin K1 has not been associated with a requirement for excessive doses of warfarin, or subtherapeutic anticoagulation, as long as the anticoagulation regimen is appropriately monitored and doses are adjusted as needed. Nonetheless, for patients on warfarin, some providers select a brand of multivitamin mix that does not contain vitamin K (eg, MVI-12).</p><p class="headingAnchor" id="H3562039529"><span class="h3">Patients on anticoagulant therapy</span><span class="headingEndMark"> — </span>Vitamin K antagonists (VKA) are a class of anticoagulant drugs whose therapeutic action depends upon antagonism of <a class="drug drug_general" data-topicid="9771" href="/z/d/drug information/9771.html" rel="external">vitamin K</a>. The dose of the drug must be carefully balanced with vitamin K intake to achieve the desired degree of anticoagulation. In a study of healthy subjects stably anticoagulated with the VKA <a class="drug drug_general" data-topicid="9159" href="/z/d/drug information/9159.html" rel="external">acenocoumarol</a>, use of food supplements providing up to 100 micrograms/day of vitamin K1 did not significantly interfere with treatment [<a href="#rid12">12</a>]. The threshold dose of vitamin K1 causing a statistically significant lowering of the international normalized ratio (INR) in these subjects was 150 micrograms/day, an amount easily exceeded following the ingestion of one-half cup of kale (<a class="graphic graphic_table graphicRef78708" href="/z/d/graphic/78708.html" rel="external">table 3</a>). Patients taking these drugs must pay attention to their dietary vitamin K intake. Maintaining a relatively stable level of intake over time is preferred to restriction. (See  <a class="medical medical_review" href="/z/d/html/1334.html" rel="external">"Warfarin and other VKAs: Dosing and adverse effects"</a>.)</p><p class="headingAnchor" id="H10"><span class="h1">VITAMIN K DEFICIENCY</span><span class="headingEndMark"> — </span>Vitamin K deficiency in an otherwise healthy child or adult is rare. This is largely due to the wide distribution of phylloquinone in plants, menaquinone production by gut micro-flora, and because vitamin K is easily recycled within cells (<a class="graphic graphic_figure graphicRef61632" href="/z/d/graphic/61632.html" rel="external">figure 2</a>). <a class="drug drug_general" data-topicid="9771" href="/z/d/drug information/9771.html" rel="external">Vitamin K</a> deficiency is common in newborn infants, prompting routine administration of vitamin K prophylaxis at birth. This is reviewed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/5068.html" rel="external">"Overview of the routine management of the healthy newborn infant", section on 'Vitamin K'</a>.)</p><p>Acquired vitamin K deficiency can occur due to drugs such as antibiotics, or other predisposing conditions as listed below. Prolonged fasting or starvation also decreases vitamin K levels. Such patients are more sensitive to treatment with coumarin-based anticoagulants [<a href="#rid13">13</a>]. (See <a class="local">'Predisposing conditions'</a> below and <a class="local">'Patients on anticoagulant therapy'</a> above.)</p><p class="headingAnchor" id="H1995367659"><span class="h2">Predisposing conditions</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9771" href="/z/d/drug information/9771.html" rel="external">Vitamin K</a> is a fat-soluble vitamin, thus any cause of fat malabsorption may result in vitamin K deficiency. Fat malabsorption may be caused by disorders of bile or pancreatic secretion, or by extensive disease or resection of the intestinal mucosa. As examples, patients with the following conditions are at risk for fat-soluble vitamin deficiencies and usually require supplementation and monitoring, as discussed in the corresponding topic reviews:</p><p class="bulletIndent1"><span class="glyph">●</span>Cystic fibrosis. (See  <a class="medical medical_review" href="/z/d/html/5882.html" rel="external">"Cystic fibrosis: Nutritional issues", section on 'Vitamin K'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Primary biliary cholangitis. (See  <a class="medical medical_review" href="/z/d/html/3623.html" rel="external">"Overview of the management of primary biliary cholangitis", section on 'Fat-soluble vitamins'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Primary sclerosing cholangitis. (See  <a class="medical medical_review" href="/z/d/html/660.html" rel="external">"Primary sclerosing cholangitis in adults: Clinical manifestations and diagnosis", section on 'Steatorrhea and vitamin deficiency'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Biliary atresia. (See  <a class="medical medical_review" href="/z/d/html/14369.html" rel="external">"Biliary atresia", section on 'Fat-soluble vitamin supplements'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Familial intrahepatic cholestasis and other inherited disorders associated with cholestasis. (See  <a class="medical medical_review" href="/z/d/html/3584.html" rel="external">"Inherited disorders associated with conjugated hyperbilirubinemia"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Intestinal diseases associated with malabsorption, such as active celiac disease, inflammatory bowel disease, or short bowel syndrome, may be associated with <a class="drug drug_general" data-topicid="9771" href="/z/d/drug information/9771.html" rel="external">vitamin K</a> deficiency. This is particularly true if the terminal ileum is involved because this can cause maldigestion of the fat-soluble vitamins by reducing the bile salt pool. (See  <a class="medical medical_review" href="/z/d/html/4774.html" rel="external">"Epidemiology, pathogenesis, and clinical manifestations of celiac disease in adults"</a> and  <a class="medical medical_review" href="/z/d/html/5887.html" rel="external">"Vitamin and mineral deficiencies in inflammatory bowel disease"</a> and  <a class="medical medical_review" href="/z/d/html/5886.html" rel="external">"Chronic complications of short bowel syndrome in children"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Liver failure – Because the vitamin K-dependent coagulation factors are synthesized in the liver, severe parenchymal liver disease also may lead to deficiencies of these factors. In patients with severe liver disease and coagulation abnormalities, measurement of factors V and VII can help to distinguish between liver parenchymal dysfunction and <a class="drug drug_general" data-topicid="9771" href="/z/d/drug information/9771.html" rel="external">vitamin K</a> malabsorption. Factor V activity does not depend on vitamin K while factor VII activity requires vitamin K as a coenzyme for carboxylation. Thus, in vitamin K malabsorption, factor V activity will be preserved while factor VII will be depressed. In liver failure, both factors V and VII activity will be impaired. (See  <a class="medical medical_review" href="/z/d/html/13932.html" rel="external">"Hemostatic abnormalities in patients with liver disease"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Medications – Medications that may contribute to <a class="drug drug_general" data-topicid="9771" href="/z/d/drug information/9771.html" rel="external">vitamin K</a> deficiency include antibiotics and high doses of <a class="drug drug_general" data-topicid="10049" href="/z/d/drug information/10049.html" rel="external">vitamin E</a>:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Antibiotics can contribute to <a class="drug drug_general" data-topicid="9771" href="/z/d/drug information/9771.html" rel="external">vitamin K</a> deficiency by affecting intestinal bacteria and also through direct effects on vitamin K activation in the liver. Most of the ingested vitamin K is absorbed in the distal small intestine. A number of microorganisms, which colonize the colon and distal ileum, synthesize absorbable vitamin K (vitamin K2, menaquinone). Many broad-spectrum antibiotics diminish this population of bacteria, limiting menaquinone production [<a href="#rid14">14</a>]. Second- and third-generation cephalosporin antibiotics are associated with hypoprothrombinemia and have a weak coumarin-like effect in patients with low vitamin K stores [<a href="#rid15">15</a>]. They cause vitamin K deficiency by inhibiting the function of vitamin K epoxide reductase enzyme in the liver, therefore impairing the recycling of vitamin K (<a class="graphic graphic_figure graphicRef61632" href="/z/d/graphic/61632.html" rel="external">figure 2</a>) [<a href="#rid15">15</a>]. (See  <a class="medical medical_review" href="/z/d/html/479.html" rel="external">"Beta-lactam antibiotics: Mechanisms of action and resistance and adverse effects", section on 'Hematologic reactions'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Very high doses of <a class="drug drug_general" data-topicid="10049" href="/z/d/drug information/10049.html" rel="external">vitamin E</a> can cause <a class="drug drug_general" data-topicid="9771" href="/z/d/drug information/9771.html" rel="external">vitamin K</a> deficiency but do not appear to affect absorption [<a href="#rid16">16</a>]. In a rat animal model, supplementation with toxic doses of <a class="drug drug_general" data-topicid="10047" href="/z/d/drug information/10047.html" rel="external">vitamin A</a> resulted in vitamin K deficiency with hypoprothrombinemia and cerebral hemorrhage [<a href="#rid17">17</a>].</p><p></p><p class="headingAnchor" id="H11"><span class="h2">Symptoms</span><span class="headingEndMark"> — </span>Clinical signs and symptoms of vitamin K deficiency include easy bruisability, mucosal bleeding, splinter hemorrhages, melena, hematuria, or any other manifestations of impaired coagulation.</p><p class="headingAnchor" id="H22930453"><span class="h2">Laboratory evaluation</span></p><p class="bulletIndent1"><span class="glyph">●</span>Symptomatic patients – For patients with bleeding symptoms, the possibility of <a class="drug drug_general" data-topicid="9771" href="/z/d/drug information/9771.html" rel="external">vitamin K</a> deficiency can be evaluated by measuring prothrombin time (PT) and international normalized ratio (INR), both of which are prolonged in vitamin K deficiency. When the deficiency is mild, only the PT may be prolonged, due to a predominant effect on factor VII. In severe vitamin K deficiency, both the PT and partial thromboplastin time (PTT) may be affected. (See  <a class="medical medical_review" href="/z/d/html/1368.html" rel="external">"Clinical use of coagulation tests", section on 'Prothrombin time (PT) and INR'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Monitoring of patients with predisposing conditions – Levels of PIVKA-II (protein induced in vitamin K absence, also known as des-gamma-carboxy prothrombin) are more sensitive than PT in detecting vitamin K deficiency and may be helpful in monitoring patients with diseases predisposing to vitamin K deficiency. PIVKA-II is also elevated in the presence of <a class="drug drug_general" data-topicid="9771" href="/z/d/drug information/9771.html" rel="external">vitamin K</a> antagonists (VKA) drugs or certain tumors such as hepatocellular carcinoma. The frequency of monitoring depends upon the type of predisposing condition and the patient's history. In patients with cystic fibrosis-related liver disease, annual monitoring with PIVKA-II or PT is recommended. (See  <a class="medical medical_review" href="/z/d/html/5882.html" rel="external">"Cystic fibrosis: Nutritional issues", section on 'Vitamin K'</a> and  <a class="medical medical_review" href="/z/d/html/5886.html" rel="external">"Chronic complications of short bowel syndrome in children", section on 'Common deficiencies'</a>.)</p><p></p><p>PT and INR are also used for monitoring anticoagulant therapy with <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">warfarin</a> or other VKA drugs. (See <a class="local">'Patients on anticoagulant therapy'</a> above and  <a class="medical medical_review" href="/z/d/html/1334.html" rel="external">"Warfarin and other VKAs: Dosing and adverse effects"</a>.)</p><p>Vitamin K status also can be determined indirectly by measuring vitamin K-dependent factors (ie, prothrombin, factors VII, IX, X, or protein C). In patients who are <a class="drug drug_general" data-topicid="9771" href="/z/d/drug information/9771.html" rel="external">vitamin K</a> deficient, levels of these factors often are less than 50 percent of normal. Phylloquinone levels also can be measured directly but are impractical for clinical use [<a href="#rid18">18,19</a>]. There are no established normal values for menaquinones.</p><p class="headingAnchor" id="H2922362410"><span class="h2">Treatment of coagulopathy</span><span class="headingEndMark"> — </span>For most adults with <a class="drug drug_general" data-topicid="9771" href="/z/d/drug information/9771.html" rel="external">vitamin K</a> deficiency and coagulopathy, we treat with a single 10 mg dose of oral vitamin K. In patients with vitamin K deficiency due to malabsorption or in those who cannot take oral medications, we administer the 10 mg dose of vitamin K parenterally (subcutaneously or intravenously).</p><p>However, in patients with generalized edema (anasarca), subcutaneous administration should be avoided due to unreliable absorption.</p><p>In addition, intravenous administration is preferred when trying to rapidly reverse coagulopathy (eg, in the setting of significant or potentially life-threatening bleeding or prior to an invasive procedure). When giving <a class="drug drug_general" data-topicid="9771" href="/z/d/drug information/9771.html" rel="external">vitamin K</a> intravenously, the infusion should be given slowly (ie, no faster than 1 mg/minute) to reduce the risk of anaphylaxis. (See  <a class="medical medical_review" href="/z/d/html/13932.html" rel="external">"Hemostatic abnormalities in patients with liver disease", section on 'General approach to managing bleeding'</a>.)</p><p>If clinical evidence of coagulopathy persists despite the administration of a single dose of <a class="drug drug_general" data-topicid="9771" href="/z/d/drug information/9771.html" rel="external">vitamin K</a>, we repeat the dose in 48 to 72 hours. </p><p>The 10 mg dose is generally more than necessary to correct the deficiency, but toxicities of <a class="drug drug_general" data-topicid="9771" href="/z/d/drug information/9771.html" rel="external">vitamin K</a> are minimal. </p><p>When vitamin K deficiency occurs in patients who are also receiving coumarin-like anticoagulants, doses of <a class="drug drug_general" data-topicid="9771" href="/z/d/drug information/9771.html" rel="external">vitamin K</a> should be minimized in order to prevent refractoriness to further anticoagulation. However, in the setting of severe coagulopathy with life-threatening bleeding, a dose reduction is not appropriate. This is discussed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/1324.html" rel="external">"Management of warfarin-associated bleeding or supratherapeutic INR", section on 'Vitamin K dose, route, formulation'</a>.)</p><p class="headingAnchor" id="H13"><span class="h1">VITAMIN K-DEFICIENT BLEEDING IN NEWBORNS AND YOUNG INFANTS</span><span class="headingEndMark"> — </span>Vitamin K deficiency is common in the newborn, and if vitamin K is not replaced, the infant is at risk for vitamin K deficiency bleeding (VKDB), previously known as hemorrhagic disease of the newborn.</p><p class="headingAnchor" id="H3352829660"><span class="h2">Pathogenesis</span><span class="headingEndMark"> — </span>Newborn infants are at risk for vitamin K deficiency because their immature liver does not efficiently utilize vitamin K. In addition, they tend to have low vitamin K stores because of the low vitamin K content of breast milk, a sterile gut, and poor placental transfer of vitamin K. In infants, the plasma concentrations of all vitamin K-dependent factors are approximately 20 percent of the adult values. Within a month after birth, the levels rise to within normal limits [<a href="#rid20">20</a>]. The risk of developing VKDB is further increased by maternal ingestion during pregnancy of <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">warfarin</a> or other coumarin-like anticoagulants, certain antibiotics (ie, cephalosporins), and some anticonvulsants [<a href="#rid21">21</a>].</p><p class="headingAnchor" id="H1734046409"><span class="h2">Clinical features</span><span class="headingEndMark"> — </span>VKDB is characterized by cutaneous bruising or bleeding from mucosal surfaces, the gastrointestinal tract, umbilicus or circumcision site, and/or intracranial hemorrhage (ICH).</p><p class="bulletIndent1"><span class="glyph">●</span>Early-onset VKDB develops within the first 24 hours of life and is usually associated with maternal medications that block <a class="drug drug_general" data-topicid="9771" href="/z/d/drug information/9771.html" rel="external">vitamin K</a> action (eg, anticonvulsants). It is associated with ICH in approximately 25 percent of affected infants [<a href="#rid22">22</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Classic VKDB develops between the second and seventh day of life and is largely prevented by administration of <a class="drug drug_general" data-topicid="9771" href="/z/d/drug information/9771.html" rel="external">vitamin K</a> at birth [<a href="#rid23">23</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Late-onset VKDB typically develops between three weeks and eight months of age. There is a high frequency of ICH in affected infants (eg, 50 percent in some series), and associated central nervous system symptoms such as vomiting or seizures may be the primary presenting symptoms [<a href="#rid24">24</a>].</p><p></p><p>Late-onset VKDB and associated ICH appear to be increasing in the United States, and these cases are associated with the parental refusal of vitamin K prophylaxis at birth, followed by exclusive breast feeding [<a href="#rid21">21,25,26</a>]. It also can be precipitated by fat malabsorption due to gastrointestinal, pancreatic, or hepatobiliary disease such as biliary atresia or cystic fibrosis, or by coumarin poisoning [<a href="#rid24">24,27</a>]. One study documented ICH due to VKDB in 21 Egyptian infants despite standard parenteral <a class="drug drug_general" data-topicid="9771" href="/z/d/drug information/9771.html" rel="external">vitamin K</a> prophylaxis at birth; risk factors included exclusive breast feeding, diarrhea, and antibiotic consumption [<a href="#rid28">28</a>].</p><p class="headingAnchor" id="H1642696466"><span class="h2">Evaluation</span><span class="headingEndMark"> — </span>The possibility of VKDB should be considered in an infant presenting during the first six months of life with bleeding, bruising, lethargy, or fussiness, especially if they are exclusively breastfed or did not receive <a class="drug drug_general" data-topicid="9771" href="/z/d/drug information/9771.html" rel="external">vitamin K</a> prophylaxis at birth. If there is a strong clinical suspicion of VKDB (eg, clinically apparent bleeding and known refusal of vitamin K prophylaxis), the infant should be treated immediately, even before test results are available. (See <a class="local">'Treatment'</a> below.)</p><p>Evaluation should include laboratory testing of prothrombin time (PT) and international normalized ratio (INR), both of which are prolonged in <a class="drug drug_general" data-topicid="9771" href="/z/d/drug information/9771.html" rel="external">vitamin K</a> deficiency. Infants with abnormal results or neurologic symptoms should have urgent neuroimaging to detect brain hemorrhage. A complete blood count with platelets and fibrinogen should also be performed to exclude other causes of bleeding. (See  <a class="medical medical_review" href="/z/d/html/6157.html" rel="external">"Stroke in the newborn: Classification, manifestations, and diagnosis"</a>.)</p><p class="headingAnchor" id="H1088124095"><span class="h2">Prevention</span><span class="headingEndMark"> — </span>All newborn infants are given <a class="drug drug_general" data-topicid="9771" href="/z/d/drug information/9771.html" rel="external">vitamin K</a> shortly after birth to prevent VKDB. This issue is discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/5068.html" rel="external">"Overview of the routine management of the healthy newborn infant", section on 'Vitamin K'</a>.)</p><p class="headingAnchor" id="H4040838767"><span class="h2">Treatment</span><span class="headingEndMark"> — </span>A presumptive diagnosis of VKDB should be made in an infant presenting with bleeding or neurologic symptoms and either prolonged PT or INR, or a history of not receiving vitamin K prophylaxis at birth. Such infants should be treated immediately with parenteral vitamin K (<a class="drug drug_general" data-topicid="9771" href="/z/d/drug information/9771.html" rel="external">phytonadione</a>), 1 to 2 mg intravenously or subcutaneously. The vitamin K dose should normalize the coagulation profile within two to three hours [<a href="#rid21">21,26</a>]. For severe bleeding episodes, fresh frozen plasma or prothrombin complex concentration may be administered in addition to vitamin K. (See  <a class="medical medical_review" href="/z/d/html/114253.html" rel="external">"Stroke in the newborn: Management and prognosis", section on 'Management of intracerebral hemorrhage'</a>.)</p><p class="headingAnchor" id="H14"><span class="h1">VITAMIN K EXCESS</span><span class="headingEndMark"> — </span>Vitamin K toxicity is very rare, and a tolerable upper limit for consumption has not been defined (<a class="graphic graphic_table graphicRef81151" href="/z/d/graphic/81151.html" rel="external">table 4</a>). Menadione, a synthetic water-soluble form of vitamin K, can cause hemolytic anemia, hyperbilirubinemia, jaundice, and kernicterus in infants [<a href="#rid29">29,30</a>]. Menadione has been used in premature or low birth weight newborns but may precipitate kernicterus in high doses [<a href="#rid31">31</a>]. However, this form of vitamin K supplementation is not available.</p><p class="headingAnchor" id="H179629381"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/110557.html" rel="external">"Society guideline links: Vitamin deficiencies"</a>.)</p><p class="headingAnchor" id="H424056764"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (see  <a class="medical medical_patient" href="/z/d/html/689.html" rel="external">"Patient education: Warfarin (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H915632"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Sources and dietary requirements</strong> – Dietary vitamin K1 (phylloquinone) is found in green vegetables like spinach and broccoli (<a class="graphic graphic_table graphicRef78708" href="/z/d/graphic/78708.html" rel="external">table 3</a>). The dietary requirement, expressed as adequate intake (AI), is 90 micrograms daily in females and 120 micrograms daily in males; the AI for children depends on age as outlined in the table (<a class="graphic graphic_table graphicRef81151" href="/z/d/graphic/81151.html" rel="external">table 4</a>). Gut micro-flora synthesizes vitamin K2 (menaquinones, including menatetrenone), which provides a portion of the dietary requirement of vitamin K. Vitamin K absorption requires intact pancreatic and biliary function and fat absorptive mechanisms. (See <a class="local">'Sources'</a> above and <a class="local">'Metabolism'</a> above and <a class="local">'Requirements'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Actions</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Vitamin K is essential for activity of several carboxylase enzymes within the hepatic cells and therefore is necessary for the activation of coagulation factors VII, IX, X, and prothrombin. The natural anticoagulant proteins S and C also require vitamin K for their activity. (See <a class="local">'Actions'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Coumarin-like anticoagulants are similar in structure to vitamin K (<a class="graphic graphic_figure graphicRef66755" href="/z/d/graphic/66755.html" rel="external">figure 1</a>) and interrupt the vitamin K-dependent carboxylation cycle (<a class="graphic graphic_figure graphicRef61632" href="/z/d/graphic/61632.html" rel="external">figure 2</a>). Vitamin K administration is one of the methods used to reverse the effects of coumarin. Patients with severely impaired liver function do not respond well to vitamin K supplementation, and coumarin-induced coagulopathy is not as easily reversed.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Vitamin K is a cofactor for some proteins involved in bone mineralization. Clinical trials have examined the use of vitamin K1 (phylloquinone) or vitamin K2 for the treatment of osteoporosis, with conflicting results. (See <a class="local">'Actions'</a> above and  <a class="medical medical_review" href="/z/d/html/2064.html" rel="external">"Overview of the management of low bone mass and osteoporosis in postmenopausal women"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9771" href="/z/d/drug information/9771.html" rel="external">Vitamin K</a> is responsible for the carboxylation of matrix gamma-carboxyglutamic acid (Gla) protein, which is thought to limit vascular calcification and hence prevent coronary artery disease. Data are inconclusive regarding whether vitamin K deficiency plays a role in coronary artery disease. (See <a class="local">'Actions'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9771" href="/z/d/drug information/9771.html" rel="external">Vitamin K</a><strong> deficiency</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Clinical signs and symptoms of vitamin K deficiency include easy bruisability, mucosal bleeding, splinter hemorrhages, melena, hematuria, or any other manifestations of impaired coagulation. Vitamin K deficiency in an otherwise healthy child or adult is rare. Patients at risk for vitamin K deficiency include those on long-term broad-spectrum antibiotics or those with fat malabsorption for a variety of reasons, including disorders of bile or pancreatic secretion, or extensive disease or resection of the intestinal mucosa. (See <a class="local">'Symptoms'</a> above and <a class="local">'Predisposing conditions'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9771" href="/z/d/drug information/9771.html" rel="external">Vitamin K</a> deficiency causes prolonged prothrombin time (PT) and International Normalized Ratio (INR). In more severe vitamin K deficiency, the partial thromboplastin time (PTT) also may be affected. Levels of PIVKA-II (proteins induced in vitamin K absence) are more sensitive than PT in detecting vitamin K deficiency and may be helpful in monitoring patients with diseases predisposing to vitamin K deficiency. (See <a class="local">'Laboratory evaluation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment of </strong><a class="drug drug_general" data-topicid="9771" href="/z/d/drug information/9771.html" rel="external">Vitamin K</a><strong> deficiency in adults</strong> – For most adults with vitamin K deficiency and coagulopathy, we treat with a single 10 mg dose of oral vitamin K. Parenteral administration is preferred in patients who cannot tolerate oral medications and when trying to rapidly reverse coagulopathy. (See <a class="local">'Treatment of coagulopathy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9771" href="/z/d/drug information/9771.html" rel="external">Vitamin K</a><strong> deficiency in newborns</strong> – Vitamin K deficiency is common in the newborn because of immature liver function and low transfer of vitamin K through the placenta or breast milk. If vitamin K prophylaxis is not administered at birth, the infant is at risk for vitamin K deficiency bleeding (VKDB), previously known as hemorrhagic disease of the newborn. This disorder is associated with cutaneous, gastrointestinal, and intracranial bleeding in neonates, typically developing within the first week of life. A late form of VKDB can present up to eight months of age, usually in exclusively breastfed infants. All newborn infants are given vitamin K shortly after birth to prevent VKDB. (See <a class="local">'Vitamin K-deficient bleeding in newborns and young infants'</a> above and  <a class="medical medical_review" href="/z/d/html/5068.html" rel="external">"Overview of the routine management of the healthy newborn infant", section on 'Vitamin K'</a>.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li class="breakAll">Food and Nutrition Board of the Institute of Medicine. Dietary Reference Intakes for Vitamin A, Vitamin K, Arsenic, Boron, Chromium, Copper, Iodine, Iron, Manganese, Molybdenum, Nickel, Silicon, Vanadium, and Zinc (2000). National Academies Press, Washington DC, 2000. p. 162-196 http://books.nap.edu/openbook.php?isbn=0309072794 (Accessed on February 20, 2018).</li><li><a class="nounderline abstract_t">Vermeer C, De Boer-Van den Berg MA. Vitamin K-dependent carboxylase. Haematologia (Budap) 1985; 18:71.</a></li><li><a class="nounderline abstract_t">Wu SM, Morris DP, Stafford DW. Identification and purification to near homogeneity of the vitamin K-dependent carboxylase. Proc Natl Acad Sci U S A 1991; 88:2236.</a></li><li><a class="nounderline abstract_t">Furie B, Furie BC. Molecular basis of vitamin K-dependent gamma-carboxylation. Blood 1990; 75:1753.</a></li><li><a class="nounderline abstract_t">Davie EW. Biochemical and molecular aspects of the coagulation cascade. Thromb Haemost 1995; 74:1.</a></li><li><a class="nounderline abstract_t">Fair DS, Marlar RA, Levin EG. Human endothelial cells synthesize protein S. Blood 1986; 67:1168.</a></li><li><a class="nounderline abstract_t">Furie B, Bouchard BA, Furie BC. Vitamin K-dependent biosynthesis of gamma-carboxyglutamic acid. Blood 1999; 93:1798.</a></li><li><a class="nounderline abstract_t">Beulens JW, Bots ML, Atsma F, et al. High dietary menaquinone intake is associated with reduced coronary calcification. Atherosclerosis 2009; 203:489.</a></li><li><a class="nounderline abstract_t">Shea MK, O'Donnell CJ, Hoffmann U, et al. Vitamin K supplementation and progression of coronary artery calcium in older men and women. Am J Clin Nutr 2009; 89:1799.</a></li><li><a class="nounderline abstract_t">Dofferhoff ASM, Piscaer I, Schurgers LJ, et al. Reduced Vitamin K Status as a Potentially Modifiable Risk Factor of Severe Coronavirus Disease 2019. Clin Infect Dis 2021; 73:e4039.</a></li><li><a class="nounderline abstract_t">Schurgers LJ, Teunissen KJ, Hamulyák K, et al. Vitamin K-containing dietary supplements: comparison of synthetic vitamin K1 and natto-derived menaquinone-7. Blood 2007; 109:3279.</a></li><li><a class="nounderline abstract_t">Schurgers LJ, Shearer MJ, Hamulyák K, et al. Effect of vitamin K intake on the stability of oral anticoagulant treatment: dose-response relationships in healthy subjects. Blood 2004; 104:2682.</a></li><li><a class="nounderline abstract_t">Cushman M, Booth SL, Possidente CJ, et al. The association of vitamin K status with warfarin sensitivity at the onset of treatment. Br J Haematol 2001; 112:572.</a></li><li><a class="nounderline abstract_t">Hooper CA, Haney BB, Stone HH. Gastrointestinal bleeding due to vitamin K deficiency in patients on parenteral cefamandole. Lancet 1980; 1:39.</a></li><li><a class="nounderline abstract_t">Shearer MJ, Bechtold H, Andrassy K, et al. Mechanism of cephalosporin-induced hypoprothrombinemia: relation to cephalosporin side chain, vitamin K metabolism, and vitamin K status. J Clin Pharmacol 1988; 28:88.</a></li><li><a class="nounderline abstract_t">Bettger WJ, Jones JP, Olson RE. Effect of alpha-tocopherol and alpha-tocopherolquinone on vitamin K-dependent carboxylation in the rat. Fed Proc 1982; 41:344.</a></li><li><a class="nounderline abstract_t">Light RF, Alscher RP, Frey CN. VITAMIN A TOXICITY AND HYPOPROTHROMBINEMIA. Science 1944; 100:225.</a></li><li><a class="nounderline abstract_t">Sadowski JA, Hood SJ, Dallal GE, Garry PJ. Phylloquinone in plasma from elderly and young adults: factors influencing its concentration. Am J Clin Nutr 1989; 50:100.</a></li><li><a class="nounderline abstract_t">Sokoll LJ, Booth SL, O'Brien ME, et al. Changes in serum osteocalcin, plasma phylloquinone, and urinary gamma-carboxyglutamic acid in response to altered intakes of dietary phylloquinone in human subjects. Am J Clin Nutr 1997; 65:779.</a></li><li><a class="nounderline abstract_t">Motohara K, Endo F, Matsuda I. Effect of vitamin K administration on acarboxy prothrombin (PIVKA-II) levels in newborns. Lancet 1985; 2:242.</a></li><li><a class="nounderline abstract_t">Shearer MJ. Vitamin K deficiency bleeding (VKDB) in early infancy. Blood Rev 2009; 23:49.</a></li><li><a class="nounderline abstract_t">Volpe JJ. Intracranial hemorrhage in early infancy--renewed importance of vitamin K deficiency. Pediatr Neurol 2014; 50:545.</a></li><li><a class="nounderline abstract_t">Sankar MJ, Chandrasekaran A, Kumar P, et al. Vitamin K prophylaxis for prevention of vitamin K deficiency bleeding: a systematic review. J Perinatol 2016; 36 Suppl 1:S29.</a></li><li><a class="nounderline abstract_t">Miyasaka M, Nosaka S, Sakai H, et al. Vitamin K deficiency bleeding with intracranial hemorrhage: focus on secondary form. Emerg Radiol 2007; 14:323.</a></li><li><a class="nounderline abstract_t">Notes from the field: Late vitamin K deficiency bleeding in infants whose parents declined Vitamin K prophylaxis — Tennessee, 2013. MMWR Morb Mortal Wkly Rep 2013; 62:901.</a></li><li><a class="nounderline abstract_t">Schulte R, Jordan LC, Morad A, et al. Rise in late onset vitamin K deficiency bleeding in young infants because of omission or refusal of prophylaxis at birth. Pediatr Neurol 2014; 50:564.</a></li><li><a class="nounderline abstract_t">Carpenter SL, Abshire TC, Anderst JD, Section on Hematology/Oncology and Committee on Child Abuse and Neglect of the American Academy of Pediatrics. Evaluating for suspected child abuse: conditions that predispose to bleeding. Pediatrics 2013; 131:e1357.</a></li><li><a class="nounderline abstract_t">Elalfy MS, Elagouza IA, Ibrahim FA, et al. Intracranial haemorrhage is linked to late onset vitamin K deficiency in infants aged 2-24 weeks. Acta Paediatr 2014; 103:e273.</a></li><li><a class="nounderline abstract_t">Badr M, Yoshihara H, Kauffman F, Thurman R. Menadione causes selective toxicity to periportal regions of the liver lobule. Toxicol Lett 1987; 35:241.</a></li><li><a class="nounderline abstract_t">Chiou TJ, Chou YT, Tzeng WF. Menadione-induced cell degeneration is related to lipid peroxidation in human cancer cells. Proc Natl Sci Counc Repub China B 1998; 22:13.</a></li><li><a class="nounderline abstract_t">Chawla D, Deorari AK, Saxena R, et al. Vitamin K1 versus vitamin K3 for prevention of subclinical vitamin deficiency: a randomized controlled trial. Indian Pediatr 2007; 44:817.</a></li></ol></div><div id="topicVersionRevision">Topic 2624 Version 48.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="http://books.nap.edu/openbook.php?isbn=0309072794" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Food and Nutrition Board of the Institute of Medicine. Dietary Reference Intakes for Vitamin A, Vitamin K, Arsenic, Boron, Chromium, Copper, Iodine, Iron, Manganese, Molybdenum, Nickel, Silicon, Vanadium, and Zinc (2000). National Academies Press, Washington DC, 2000. p. 162-196 http://books.nap.edu/openbook.php?isbn=0309072794 (Accessed on February 20, 2018).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3896983" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Vitamin K-dependent carboxylase.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2006163" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Identification and purification to near homogeneity of the vitamin K-dependent carboxylase.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2184900" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Molecular basis of vitamin K-dependent gamma-carboxylation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8578439" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Biochemical and molecular aspects of the coagulation cascade.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2937470" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Human endothelial cells synthesize protein S.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10068650" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Vitamin K-dependent biosynthesis of gamma-carboxyglutamic acid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18722618" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : High dietary menaquinone intake is associated with reduced coronary calcification.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19386744" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Vitamin K supplementation and progression of coronary artery calcium in older men and women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32852539" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Reduced Vitamin K Status as a Potentially Modifiable Risk Factor of Severe Coronavirus Disease 2019.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17158229" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Vitamin K-containing dietary supplements: comparison of synthetic vitamin K1 and natto-derived menaquinone-7.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15231565" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Effect of vitamin K intake on the stability of oral anticoagulant treatment: dose-response relationships in healthy subjects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11260056" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : The association of vitamin K status with warfarin sensitivity at the onset of treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6101371" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Gastrointestinal bleeding due to vitamin K deficiency in patients on parenteral cefamandole.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3350995" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Mechanism of cephalosporin-induced hypoprothrombinemia: relation to cephalosporin side chain, vitamin K metabolism, and vitamin K status.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Effect of alpha-tocopherol and alpha-tocopherolquinone on vitamin K-dependent carboxylation in the rat</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17840410" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : VITAMIN A TOXICITY AND HYPOPROTHROMBINEMIA.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2750682" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Phylloquinone in plasma from elderly and young adults: factors influencing its concentration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9062529" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Changes in serum osteocalcin, plasma phylloquinone, and urinary gamma-carboxyglutamic acid in response to altered intakes of dietary phylloquinone in human subjects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2862419" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Effect of vitamin K administration on acarboxy prothrombin (PIVKA-II) levels in newborns.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18804903" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Vitamin K deficiency bleeding (VKDB) in early infancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24842253" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Intracranial hemorrhage in early infancy--renewed importance of vitamin K deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27109090" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Vitamin K prophylaxis for prevention of vitamin K deficiency bleeding: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17786492" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Vitamin K deficiency bleeding with intracranial hemorrhage: focus on secondary form.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Notes from the field: Late vitamin K deficiency bleeding in infants whose parents declined Vitamin K prophylaxis—Tennessee, 2013</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24842255" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Rise in late onset vitamin K deficiency bleeding in young infants because of omission or refusal of prophylaxis at birth.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23530171" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Evaluating for suspected child abuse: conditions that predispose to bleeding.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24528309" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Intracranial haemorrhage is linked to late onset vitamin K deficiency in infants aged 2-24 weeks.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3824412" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Menadione causes selective toxicity to periportal regions of the liver lobule.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9536516" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Menadione-induced cell degeneration is related to lipid peroxidation in human cancer cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18057477" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Vitamin K1 versus vitamin K3 for prevention of subclinical vitamin deficiency: a randomized controlled trial.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
